Multiple Myeloma · Lenalidomide maintenance post-ASCT (CALGB 100104 / IFM 2005-02 schedule)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | REG-LENALIDOMIDE-MAINTENANCE |
| ID | IND-MM-POST-ASCT-LENALIDOMIDE-MAINTENANCE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MM |
| Sources | SRC-ESMO-MM-2023 SRC-NCCN-MM-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track post-ASCT consolidation. line_of_therapy: 1 reflects "1L pathway" continuation rather than "2nd line" — maintenance is part of the 1L plan in MM. Engine should activate this Indication after ASCT decision tree completes. Bortezomib / ixazomib / lenalidomide-bortezomib doublet alternatives are separate future Indications.
Used By
Algorithms
ALGO-MM-2L- ALGO-MM-2L